查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095766

生物製藥合約開發市場－2026-2032年全球市場預測

Biologics Contract Development Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物製藥合約開發市場將成長至 182.9 億美元，複合年成長率為 12.18%。

主要市場統計數據
基準年 2025 81.7億美元
預計年份：2026年 91.5億美元
預測年份 2032 182.9億美元
複合年成長率 (%) 12.18%

生物製藥合約開發執行摘要

生物製藥合約開發已成為生物製藥公司的策略支柱，旨在加速複雜療法的開發，涵蓋從藥物發現到臨床試驗準備的各個階段，同時有效管理科學、營運和監管風險。該領域涵蓋細胞株開發、製程開發、分析方法開發、製劑開發、穩定性測試、技術轉移以及臨床生產支持，涉及單株抗體、重組蛋白、疫苗、細胞和基因療法以及新一代生物製藥產品。不斷成長的生物製藥研發管線、日益複雜的分子結構、不斷提高的品質要求以及對良好生產規範 (GMP) 合規性、可比性和監管文件方面的專業知識的需求，共同推動了這一領域的發展。

生物製藥合約開發格局的變革性變化。

隨著申辦方從分散的外包模式轉向整合的端到端開發模式，生物製藥合約開發格局正在經歷結構性轉變。早期生物製藥計畫越來越需要在細胞株工程、上下游製程最佳化、分析可比性、製劑開發和臨床供應計畫等各個環節進行協作。這推動了對能夠降低過渡風險、保持資料連續性並支援技術轉移到現有良好生產規範 (cGMP) 環境下的開發合作夥伴的需求。

人工智慧對生物製藥合約開發的累積影響。

人工智慧 (AI) 透過改進決策、加速實驗設計以及增強製程可預測性，對整個生物製藥合約開發流程產生著累積的影響。在開發初期，機器學習模型被用於支援蛋白質工程、可行性評估、細胞株選擇、表現最佳化和免疫抗原性風險評估。這些工具有助於在進行資源密集型實驗工作之前，優先篩選出穩定性、溶解性、可生產性和安全性較佳的候選物質。

生物製藥合約開發的關鍵區域洞察

亞太地區正逐漸成為生物製藥合約開發的重要樞紐，這主要得益於生物製藥研究的拓展、臨床試驗活動的活性化、政府對生物技術基礎設施的投資以及主要經濟體監管體系的日趨成熟。中國、印度、日本、韓國、新加坡和澳洲正在加強其在細胞株開發、生物相似藥開發、生技藥品分析檢測和先進療法開發方面的能力。儘管該地區擁有科學人才、不斷發展的生產生態系統和政府主導的生物技術戰略等優勢，但申辦方在選擇合作夥伴時，仍會評估其品質系統、智慧財產權保護和跨境資料要求。

全球生技藥品開發網路的關鍵小組見解

隨著新加坡、馬來西亞、泰國、印尼、越南和菲律賓等國建構生物技術生態系統、臨床研究能力和藥品生產能力，東協在生物製劑合約開發領域的重要性日益凸顯。新加坡以其先進的生物醫學基礎設施、清晰的法規環境和高素質的勞動力而廣受認可，但其他東協成員國也對本地生產和加強醫療服務可及性表現出越來越濃厚的興趣。東協在生物製劑開發領域的作用與跨區域監管協調、投資激勵措施以及融入全球臨床和供應鏈網路密切相關。

主要國家生物製藥合約開發趨勢

美國憑藉其生物技術創新、臨床研究活動、監管專業知識和先進的研發基礎設施，在生物製藥合約開發領域處於主導。單株抗體、細胞和基因療法、疫苗、重組蛋白和新型生物製藥製劑的需求強勁。加拿大透過其公共生物製造舉措、強大的學術研究實力以及在疫苗、生物製藥分析和臨床開發方面的先進能力，對北美地區的能力進行了補充。

為生物製藥合約開發領域的領導者提供實用建議。

產業領導者應將生物製藥合約開發視為一項策略能力決策，而不僅僅是採購活動。在選擇合作夥伴時，應優先考慮其在特定療法領域的專業知識、監管合規記錄、品質文化、分析深度、技術轉移經驗，以及從早期可行性評估到臨床生產準備階段，以支持研發連續性的能力。申辦方應評估潛在合作夥伴是否能夠管理關鍵品質屬性、建立健全的控制策略，並準備適用於與全球監管機構溝通的文件。

基於證據的生物製藥研發調查方法

本執行摘要採用系統化的二手研究途徑編寫，重點關注檢驗、公開且業界認可的資訊來源。調查方法包括分析監管指南、公共衛生機構出版刊物、臨床試驗趨勢、科學文獻、生物製程技術進展、政府生物技術計劃、貿易和政策文件，以及與生技藥品的開發、分析表徵、生產準備和先進治療方式相關的同行評審研究舉措。

結論：生物製藥合約開發的策略展望

生物製藥的合約開發正步入一個更加複雜、技術驅動且具有戰略意義的關鍵階段。委託方面臨著在推動日益複雜的生物製藥模式開發的同時，保持科學嚴謹性、符合監管要求和供應鏈穩定性的壓力。因此，如今對合約開發合作夥伴的評估不僅包括其技術執行能力，還包括其整合開發策略、強大的分析能力、數位化成熟度和全球監管合規能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：生物製藥合約開發市場：依服務類型分類

  • 商業生產
  • 填充和精加工
  • 製程開發
    • 下游開發
    • 上游工程開發

第8章：生物製藥合約開發市場：依分子類型分類

  • 細胞和基因治療
  • 單株抗體
    • 雙特異性抗體
    • 組合型
  • 重組蛋白
  • 疫苗
    • 細菌
    • mRNA
    • 病毒性的

第9章：生物製藥合約開發市場：依宿主系統分類

  • 哺乳動物
  • 微生物
  • 東方

第10章：生物製藥合約開發市場：依技術分類

  • 連續製造
    • 灌注
    • 單一途徑
  • 免洗系統
  • 不銹鋼系統

第11章：生物製藥合約開發市場：依最終用戶分類

  • 生物製藥公司
  • 契約製造組織
  • 製藥公司

第12章：生物製藥合約開發市場：依治療領域分類

  • 自體免疫疾病
  • 心血管系統
  • 感染疾病
  • 腫瘤學
    • 血液學
    • 固體癌

第13章：生物製藥合約開發市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：生物製藥合約開發市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生物製藥合約開發市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie, Inc.
  • Abzena Ltd.
  • Aenova Holding GmbH
  • AGC Biologics GmbH
  • Alcami Corporation
  • Avid Bioservices, Inc.
  • BioFactura, Inc.
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Celltrion Inc.
  • Curia Global, Inc.
  • Emergent BioSolutions, Inc.
  • Fujifilm Holdings Corporation
  • KBI Biopharma
  • Lonza Group AG
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Selexis SA
  • Thermo Fisher Scientific, Inc.
  • Wacker Chemie AG
  • WuXi Biologics Inc.
Product Code: MRR-957C47F8FF75

The Biologics Contract Development Market is projected to grow by USD 18.29 billion at a CAGR of 12.18% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.17 billion
Estimated Year [2026] USD 9.15 billion
Forecast Year [2032] USD 18.29 billion
CAGR (%) 12.18%

Biologics Contract Development Executive Summary

Biologics contract development has become a strategic pillar for biopharmaceutical organizations seeking to accelerate complex therapies from discovery through clinical readiness while managing scientific, operational, and regulatory risk. The field spans cell line development, process development, analytical method development, formulation, stability testing, technology transfer, and clinical manufacturing support for monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, and next-generation biologic modalities. Demand is being shaped by expanding biologics pipelines, increasing molecular complexity, tighter quality expectations, and the need for specialized expertise in good manufacturing practice readiness, comparability, and regulatory documentation.

Unlike small-molecule development, biologics contract development requires deep control of living systems, raw material variability, critical quality attributes, and advanced analytical characterization. As sponsors pursue faster development timelines and more flexible operating models, contract development partners are increasingly valued for integrated scientific capabilities, scalable platforms, quality-by-design frameworks, and experience with global regulatory submissions. The sector is also being influenced by advances in single-use technologies, continuous bioprocessing, high-throughput screening, digital quality systems, and artificial intelligence-enabled development workflows.

For industry leaders, biologics contract development is no longer a transactional outsourcing decision. It is a strategic choice that affects speed to clinic, manufacturing robustness, regulatory confidence, cost discipline, and long-term supply resilience.

Transformative Shifts in the Biologics Contract Development Landscape

The biologics contract development landscape is undergoing structural change as sponsors move from fragmented outsourcing toward integrated, end-to-end development models. Early-stage biologics programs increasingly require coordinated execution across cell line engineering, upstream and downstream process optimization, analytical comparability, formulation, and clinical supply planning. This is driving demand for development partners that can reduce handoff risk, preserve data continuity, and support technology transfer into current good manufacturing practice environments.

Scientific complexity is another major shift. Antibody formats, bispecifics, antibody-drug conjugates, viral vectors, mRNA-based biologics, recombinant vaccines, and cell therapies each require distinct development strategies, specialized assays, and tailored manufacturing platforms. As a result, platform standardization is being balanced with modality-specific customization. Quality-by-design principles are increasingly embedded earlier in development, with emphasis on critical process parameters, critical quality attributes, process characterization, and control strategies that can withstand regulatory review.

Operationally, the sector is becoming more resilient and geographically diversified. Supply chain disruptions during recent global health emergencies highlighted the importance of dual sourcing, regional development capacity, secure cold-chain planning, and robust raw material qualification. Sponsors are also placing greater emphasis on data integrity, cybersecurity, environmental sustainability, and regulatory harmonization. These shifts are positioning biologics contract development providers as long-term innovation partners rather than capacity suppliers.

Cumulative Impact of Artificial Intelligence on Biologics Contract Development

Artificial intelligence is creating a cumulative impact across biologics contract development by improving decision-making, accelerating experimental design, and strengthening process predictability. In early development, machine learning models are being used to support protein engineering, developability assessment, cell line selection, expression optimization, and immunogenicity risk evaluation. These tools can help prioritize candidates with more favorable stability, solubility, manufacturability, and safety-related profiles before resource-intensive laboratory work begins.

In process development, AI-enabled design of experiments, predictive modeling, and advanced analytics are improving the ability to identify optimal upstream and downstream conditions. Applications include media optimization, bioreactor parameter control, chromatography strategy refinement, yield improvement, impurity reduction, and root-cause analysis. When combined with high-throughput experimentation and automation, AI can shorten iteration cycles and increase the scientific value of development data.

AI is also influencing analytical development and quality operations. Pattern recognition tools can support interpretation of complex datasets from chromatography, mass spectrometry, capillary electrophoresis, imaging, and sensor-based monitoring. Digital quality systems can enhance deviation management, batch record review, documentation consistency, and regulatory traceability. However, adoption requires validated models, explainable outputs, governed data environments, and alignment with regulatory expectations for computerized systems, data integrity, and human oversight.

The cumulative effect is a shift from reactive troubleshooting toward predictive and adaptive biologics development. Organizations that combine AI with strong scientific governance, high-quality datasets, and validated workflows are better positioned to improve development efficiency without compromising regulatory rigor.

Key Regional Insights for Biologics Contract Development

Asia-Pacific is becoming a central geography for biologics contract development due to expanding biopharmaceutical research, growing clinical trial activity, public investment in biotechnology infrastructure, and increasing regulatory maturity across major economies. China, India, Japan, South Korea, Singapore, and Australia are strengthening capabilities in cell line development, biosimilar development, biologics analytical testing, and advanced therapy development. The region benefits from scientific talent, evolving manufacturing ecosystems, and government-backed biotechnology strategies, while sponsors continue to evaluate quality systems, intellectual property protection, and cross-border data requirements when selecting partners.

North America remains a leading center for high-complexity biologics development, supported by deep biotechnology innovation, mature regulatory frameworks, advanced clinical research networks, and extensive expertise in monoclonal antibodies, recombinant proteins, cell therapies, gene therapies, and vaccines. The United States is particularly influential in regulatory science, venture-backed biologics innovation, and specialized development services, while Canada contributes through academic research, biomanufacturing initiatives, and clinical development capacity. Regional priorities include speed to clinic, quality compliance, modality expertise, and secure supply chains.

Latin America is gaining relevance as a biologics development and clinical research region, with Brazil and Mexico serving as important centers for regulatory modernization, local biopharmaceutical capability, and participation in global clinical development. Although the region's contract development infrastructure is less mature than North America, Europe, and parts of Asia-Pacific, demand is supported by biosimilar interest, public health needs, and regional efforts to strengthen local production of complex medicines.

Europe is distinguished by strong regulatory oversight, established bioprocessing expertise, advanced academic-industry collaboration, and a concentration of biologics development capabilities across Germany, France, the United Kingdom, Italy, Spain, the Netherlands, Belgium, Switzerland, and the Nordic countries. European stakeholders place strong emphasis on quality, comparability, sustainability, data protection, and compliance with stringent medicinal product standards. The region is also important for biosimilars, advanced therapy medicinal products, and collaborative research networks.

The Middle East is emerging as a strategic region for biopharmaceutical localization, supported by healthcare diversification agendas, investment in life sciences infrastructure, and initiatives to reduce dependence on imported medicines. Gulf economies are prioritizing pharmaceutical security, clinical research growth, and biotechnology clusters, although biologics contract development capabilities remain in earlier stages compared with mature markets.

Africa is at an early but strategically important stage in biologics development, with increasing attention on vaccine manufacturing, public health preparedness, local production capacity, and technology transfer. Regional initiatives supported by public institutions and international health organizations are focused on building regulatory capacity, workforce skills, and manufacturing readiness. Long-term development depends on infrastructure investment, stable policy environments, quality system maturation, and regional collaboration.

Key Group Insights Across Global Biologics Development Networks

ASEAN is increasingly relevant to biologics contract development as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines build biotechnology ecosystems, clinical research capacity, and pharmaceutical manufacturing capabilities. Singapore is widely recognized for advanced biomedical infrastructure, regulatory clarity, and skilled talent, while other ASEAN members are strengthening local production ambitions and healthcare access. The group's role in biologics development is linked to regional harmonization, investment incentives, and integration into global clinical and supply networks.

The GCC is positioning life sciences as part of broader economic diversification and healthcare resilience strategies. Member states are investing in biotechnology parks, clinical research frameworks, digital health systems, and local manufacturing initiatives. For biologics contract development, the GCC's opportunity lies in regional clinical access, cold-chain logistics modernization, and government-backed localization, although specialized biologics process development and analytical development infrastructure continues to evolve.

The European Union provides one of the most harmonized regulatory environments for biologics, supported by centralized medicinal product evaluation pathways, stringent pharmacovigilance expectations, and strong standards for good manufacturing practice. The EU's biologics contract development environment benefits from cross-border research collaboration, advanced bioprocessing talent, and policy emphasis on strategic autonomy in medicines supply. Sustainability, data protection, and regulatory compliance are particularly important considerations for sponsors operating in the region.

BRICS countries represent a diverse biologics contract development landscape with strong relevance to biosimilars, vaccine development, local manufacturing, and access-focused healthcare strategies. China and India are major contributors to development and manufacturing capacity, Brazil and South Africa are important for regional health priorities and clinical research, and Russia maintains scientific and pharmaceutical infrastructure despite geopolitical and trade-related constraints. BRICS markets collectively underscore the importance of cost-efficient development, technology transfer, and domestic biopharmaceutical capability.

G7 countries remain highly influential in biologics innovation, regulatory science, intellectual property frameworks, and advanced therapy development. The group includes several of the world's most mature biopharmaceutical ecosystems, with strong academic research, clinical trial infrastructure, and quality expectations. Biologics contract development activity in G7 economies is closely associated with complex modalities, early regulatory engagement, advanced analytics, and high standards for data integrity.

NATO members overlap significantly with major biopharmaceutical economies in North America and Europe, making the group relevant from the perspective of supply chain security, health preparedness, and strategic manufacturing resilience. While NATO itself is not a pharmaceutical regulator or market authority, member countries have heightened focus on secure access to critical medicines, resilient logistics, cybersecurity, and emergency readiness, all of which influence biologics development and manufacturing strategies.

Key Country Insights in Biologics Contract Development

The United States is a dominant force in biologics contract development due to its concentration of biotechnology innovation, clinical research activity, regulatory expertise, and advanced development infrastructure. Demand is strongly influenced by monoclonal antibodies, cell and gene therapies, vaccines, recombinant proteins, and novel biologic formats. Canada complements North American capacity through public biomanufacturing initiatives, academic research strengths, and growing capabilities in vaccines, biologics analytics, and clinical development.

Mexico is strengthening its pharmaceutical manufacturing and clinical research relevance, supported by proximity to the United States, evolving regulatory capabilities, and interest in regional supply chain resilience. Brazil is Latin America's most significant biologics ecosystem, with established public health institutions, biosimilar activity, vaccine capabilities, and regulatory experience that support regional development ambitions.

The United Kingdom remains a strong biologics development hub, supported by advanced life sciences research, clinical trial expertise, and capabilities in cell and gene therapy, biologics analytics, and translational medicine. Germany is a leading European center for bioprocessing, engineering excellence, analytical science, and biologics manufacturing readiness. France combines strong biomedical research, vaccine expertise, and policy support for pharmaceutical sovereignty. Russia has longstanding scientific and pharmaceutical capabilities, particularly in vaccines and biologics, though international collaboration and supply chains are affected by geopolitical constraints. Italy and Spain contribute through clinical research networks, manufacturing infrastructure, and growing biologics and biosimilar development activities.

China has rapidly expanded biologics development capacity through major investment in biotechnology, clinical trials, biosimilars, innovative antibodies, and cell therapies. The country's regulatory reforms have improved review processes and alignment with international development standards, although sponsors continue to assess data governance, intellectual property, and geopolitical considerations. India is a major biologics and biosimilar development country, supported by scientific talent, cost-efficient development models, vaccine expertise, and expanding regulatory capabilities. Japan remains highly important for quality-driven biologics development, advanced research, and regulatory sophistication, with strong demand for reliable development partners able to meet stringent standards. Australia offers strong early-stage clinical trial capabilities, regulatory efficiency for clinical research, and high-quality biomedical infrastructure, making it attractive for translational development. South Korea has become a recognized biologics and biosimilars center, supported by government investment, advanced manufacturing infrastructure, and growing expertise in cell therapy, antibody development, and bioprocessing.

Actionable Recommendations for Biologics Contract Development Leaders

Industry leaders should treat biologics contract development as a strategic capability decision rather than a procurement exercise. Partner selection should prioritize modality-specific expertise, regulatory track record, quality culture, analytical depth, technology transfer experience, and the ability to support development continuity from early feasibility through clinical manufacturing readiness. Sponsors should assess whether potential partners can manage critical quality attributes, establish robust control strategies, and generate documentation suitable for global regulatory interactions.

Organizations should invest in integrated development planning that aligns cell line development, upstream process design, downstream purification, formulation, analytical methods, stability strategy, and clinical supply requirements from the beginning of the program. Early adoption of quality-by-design, risk-based development, and comparability planning can reduce late-stage rework and strengthen regulatory confidence. Sponsors should also build governance models that define decision rights, data ownership, change control, deviation management, and escalation pathways.

To improve resilience, leaders should diversify supply networks, qualify critical raw material sources, evaluate regional development options, and plan technology transfer well before capacity constraints emerge. Artificial intelligence and automation should be adopted selectively in areas where data quality, validation, explainability, and regulatory acceptance can be demonstrated. Finally, sustainability, cybersecurity, and digital data integrity should be embedded into partner evaluations, as these factors increasingly influence regulatory, operational, and reputational risk.

Research Methodology for Evidence-Based Biologics Development Insights

This executive summary is developed through a structured secondary research approach focused on verified, publicly available, and industry-recognized sources. The methodology includes analysis of regulatory guidance, public health agency publications, clinical trial trends, scientific literature, bioprocessing technology developments, government biotechnology initiatives, trade and policy documents, and peer-reviewed insights related to biologics development, analytical characterization, manufacturing readiness, and advanced therapy modalities.

The research framework emphasizes triangulation across multiple source categories to reduce bias and improve reliability. Regulatory perspectives are assessed through guidance and public communications from recognized health authorities and international harmonization bodies. Scientific and technical insights are evaluated through peer-reviewed publications, biomanufacturing references, and documented developments in process intensification, analytical technologies, automation, and artificial intelligence. Regional and country insights are informed by public policy initiatives, healthcare infrastructure developments, clinical research activity, and biopharmaceutical ecosystem indicators.

The methodology deliberately excludes market sizing, revenue estimation, market share ranking, and forecasting. Instead, it focuses on qualitative and evidence-based interpretation of structural trends, capability development, regulatory direction, technology adoption, and strategic implications for biologics contract development stakeholders.

Conclusion: Strategic Outlook for Biologics Contract Development

Biologics contract development is entering a more complex, technology-enabled, and strategically important phase. Sponsors are under pressure to advance increasingly sophisticated biologic modalities while maintaining scientific rigor, regulatory compliance, and supply resilience. As a result, contract development partners are being evaluated not only for technical execution but also for their ability to provide integrated development strategy, robust analytics, digital maturity, and global regulatory readiness.

Artificial intelligence, automation, quality-by-design, single-use systems, and advanced analytical platforms are reshaping how biologics are developed, characterized, and transferred into clinical manufacturing. At the same time, regional diversification across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa is redefining access to talent, infrastructure, and resilient supply networks.

Organizations that align biologics contract development strategy with modality requirements, regional opportunity, regulatory expectations, and data-driven execution will be better positioned to reduce development risk and improve clinical readiness. The most successful stakeholders will combine scientific specialization with operational discipline, digital governance, and long-term partnership models that support the next generation of biologic medicines.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biologics Contract Development Market, by Service Type

  • 7.1. Introduction
  • 7.2. Commercial Manufacturing
  • 7.3. Fill Finish
  • 7.4. Process Development
    • 7.4.1. Downstream Development
    • 7.4.2. Upstream Development

8. Biologics Contract Development Market, by Molecule Type

  • 8.1. Introduction
  • 8.2. Cell Gene Therapy
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Bispecific
    • 8.3.2. Conjugated
  • 8.4. Recombinant Proteins
  • 8.5. Vaccines
    • 8.5.1. Bacterial
    • 8.5.2. mRNA
    • 8.5.3. Viral

9. Biologics Contract Development Market, by Host System

  • 9.1. Introduction
  • 9.2. Mammalian
  • 9.3. Microbial
  • 9.4. Yeast

10. Biologics Contract Development Market, by Technology

  • 10.1. Introduction
  • 10.2. Continuous Manufacturing
    • 10.2.1. Perfusion
    • 10.2.2. Single Pass
  • 10.3. Single Use Systems
  • 10.4. Stainless Steel Systems

11. Biologics Contract Development Market, by End User

  • 11.1. Introduction
  • 11.2. Biopharmaceutical Companies
  • 11.3. Contract Manufacturing Organizations
  • 11.4. Pharmaceutical Companies

12. Biologics Contract Development Market, by Therapeutic Area

  • 12.1. Introduction
  • 12.2. Autoimmune Disorders
  • 12.3. Cardiovascular
  • 12.4. Infectious Diseases
  • 12.5. Oncology
    • 12.5.1. Hematology
    • 12.5.2. Solid Tumors

13. Biologics Contract Development Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Biologics Contract Development Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biologics Contract Development Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie, Inc.
  • 17.2. Abzena Ltd.
  • 17.3. Aenova Holding GmbH
  • 17.4. AGC Biologics GmbH
  • 17.5. Alcami Corporation
  • 17.6. Avid Bioservices, Inc.
  • 17.7. BioFactura, Inc.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Cambrex Corporation
  • 17.10. Catalent, Inc.
  • 17.11. Celltrion Inc.
  • 17.12. Curia Global, Inc.
  • 17.13. Emergent BioSolutions, Inc.
  • 17.14. Fujifilm Holdings Corporation
  • 17.15. KBI Biopharma
  • 17.16. Lonza Group AG
  • 17.17. ProBioGen AG
  • 17.18. Recipharm AB
  • 17.19. Rentschler Biopharma SE
  • 17.20. Samsung Biologics
  • 17.21. Selexis SA
  • 17.22. Thermo Fisher Scientific, Inc.
  • 17.23. Wacker Chemie AG
  • 17.24. WuXi Biologics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMMERCIAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMMERCIAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMMERCIAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FILL FINISH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FILL FINISH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FILL FINISH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DOWNSTREAM DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DOWNSTREAM DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DOWNSTREAM DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL UPSTREAM DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UPSTREAM DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UPSTREAM DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BISPECIFIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BISPECIFIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BISPECIFIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONJUGATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONJUGATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONJUGATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MAMMALIAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MAMMALIAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MAMMALIAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MICROBIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MICROBIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MICROBIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL YEAST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL YEAST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL YEAST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PERFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PERFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SINGLE PASS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SINGLE PASS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SINGLE PASS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SINGLE USE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SINGLE USE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SINGLE USE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL STAINLESS STEEL SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL STAINLESS STEEL SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL STAINLESS STEEL SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HEMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HEMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 194. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 195. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 197. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 199. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 227. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 229. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 230. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 231. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 233. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 239. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 241. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 242. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 243. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 245. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 284. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 314. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 315. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 318. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 320. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 326. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 327. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 328. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 330. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 332. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. RUSSIA BIOLOGICS CONTRACT DEVELOPMENT M